| Bioactivity | KX1-004 is a potent and non-ATP competitive Src-PTK inhibitor with an IC50 of 40 μM. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL)[1][2]. | ||||||||||||
| In Vivo | KX1-004 (30 µM) provides significant protection against noise-induced temporary threshold shift (TTS), permanent threshold shift (PTS) and outer hair cells (OHC) loss[1].KX1-004 (50 mg/kg) is effective against noise exposure[2]. | ||||||||||||
| Name | KX1-004 | ||||||||||||
| CAS | 518058-84-9 | ||||||||||||
| Formula | C16H13FN2O2 | ||||||||||||
| Molar Mass | 284.29 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Harris KC, et al. Prevention of noise-induced hearing loss with Src-PTK inhibitors. Hear Res. 2005 Oct;208(1-2):14-25. [2]. Bielefeld EC, et al. A comparison of the protective effects of systemic administration of a pro-glutathione drug and a Src-PTK inhibitor against noise-induced hearing loss. Noise Health. 2005 Oct-Dec;7(29):24-30. |